| abstract |
A compound having the structure: A compound having the structure (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A and A' are independently C or N, where C may be unsubstituted or substituted by halo or C 1 -C 6 alkyl; R and R 0 are independently selected from the group consisting of H, C 1 -C 6 alkyl, hydroxy(C 1 -C 6 alkyl), phenyl(C 1 -C 6 alkyl), and -(CH 2 ) n -W, where W is C 3 -C 8 cycloalkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing 1 -3 N, S and/or 0 atoms, -SO 2 -R', -NHSO 2 -R', -NR"SO 2 -R' and SR', where R' and R" are independently C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl, etc.; wherein each of said alkyl, cycloalkyl, heterocyclic, phenyl, naphthyl or heteroaryl may be unsubstituted or substituted by phenyl, heteroaryl, etc.; or, R and R 0 and the N atom to which they are bonded together form a monocyclic or bicyclic heterocyclic ring which may be unsubstituted or substituted by (a) halo, hydroxy, heteroaryl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, etc., or (b) -(CH 2 ) n -W, where W is C 3 -C 8 cycloalkyl, phenyl, etc.; R 1 is H, halo or cyano; R 2 and R 2' are independently H, C 1 -C 6 alkyl, cyano, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, or C 3 -C 8 cycloalkyl where alkyl, alkoxy, or cycloalkyl is optionally substituted by one or more fluorine atoms; X is a bond, -CO-, -CONH-, -S0 2 -, -SONH-, or -(CH 2 ) m -; R 3 is H, C 1 -C 4 alkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing 1 -3 N atoms, a 5-membered heteroaryl or heterocyclic, etc., or (c) 2 O or S atoms and 0-2 N atoms; wherein each of said phenyl, naphthyl, heteroaryl or heterocyclic is optionally substituted by alkyl, 1 substituent -Y-R 4 and/or 1 -4 substituents each independently selected from R 5 ; with the proviso that when X is -CO- or -SO 2 -, R 3 is not H; Y is a bond, -(CH 2 ) m - or -O-; R 4 is (a) H, C 1 -C 6 alkyl, C 3 -C 8 cycloalkl, halo, oxo, -OR 6 , -NR 7 R 8 , -SR 6, -SOR 9 , -SO 2 R 9 , -COR 6 , -OCOR 6 , -COOR 6 , -NR 6 COR 6 , -CONR 7 R 8 , etc.; (b) phenyl or naphthyl, said phenyl and naphthyl being optionally substituted with 1 -5 substituents selected from C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, halo, cyano, -OR 6 , -NR 7 R 8, etc.; or (c) a 3 to 8-membered saturated or partially unsaturated monocyclic heteroaryl, etc.; R 6 is H, C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl, etc.; R 7 and R 8 are each independently H, C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl or are taken together with the nitrogen atom to which they are attached to form a 4-, 5- or 6-membered saturated heterocyclic ring containing 1 -2 nitrogen atoms or 1 nitrogen and 1 oxygen atom, said C 1 -C 6 alkyl is optionally substituted by C 3 -C 8 cycloalkyl, ha lo, etc., and said heterocyclic ring being optionally substituted by one or more C 1 -C 6 alkyl or C 3 -C 8 cycloalkyli groups; R 9 is C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl; and, m and n are independently 0, 1, 2 or 3. The invention also relates to pharmaceutically acceptable salts of these compounds and to pharmaceutically acceptable solvates thereof; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD. |